Abstract is: Willy Rozenbaum (born 25 June 1945) is a Polish-born French physician. A co-discoverer of the human immunodeficiency virus (HIV) with Jean-Claude Chermann of Luc Montagnier's team, he has since 19 November 2003 held the chair of France's "conseil national du SIDA" (National Council on AIDS) and before that had since 1989 practiced in the infectious and tropical diseases service at l'fr and been professor of infectious and tropical diseases at l'Hôpital Saint-Antoine in Paris.
| human | Q5 |
| P3630 | Babelio author ID | 108721 |
| P5695 | Bibliopoche author ID | 13389 |
| P268 | Bibliothèque nationale de France ID | 12013542p |
| P8179 | Canadiana Name Authority ID | ncf11172891 |
| P11496 | CiNii Research ID | 1140282266553660544 |
| P6178 | Dimensions author ID | 01314166160.01 |
| P646 | Freebase ID | /m/0gffjvh |
| P269 | IdRef ID | 028263790 |
| P213 | ISNI | 0000000066408659 |
| P244 | Library of Congress authority ID | n85058576 |
| P271 | NACSIS-CAT author ID | DA06713131 |
| P8189 | National Library of Israel J9U ID | 987007394615205171 |
| P349 | NDL Authority ID | 00474143 |
| P1207 | NUKAT ID | n2019015370 |
| P496 | ORCID iD | 0000-0003-1975-3566 |
| P1005 | Portuguese National Library author ID | 200974 |
| P10780 | Radio France person ID | willy-rozenbaum |
| P3065 | RERO ID (obsolete) | 02-A003767953 |
| P1153 | Scopus author ID | 7005578570 |
| P214 | VIAF ID | 7401351 |
| P4124 | Who's Who in France biography ID | 30791 |
| P10832 | WorldCat Entities ID | E39PBJtCxcMvhwqrXkKBdhkkXd |
| P2002 | X username | wirozen |
| P27 | country of citizenship | France | Q142 |
| P734 | family name | Rozenbaum | Q37079891 |
| Rozenbaum | Q37079891 | ||
| Rozenbaum | Q37079891 | ||
| P101 | field of work | HIV/AIDS | Q12199 |
| P735 | given name | Willy | Q1459646 |
| Willy | Q1459646 | ||
| P1412 | languages spoken, written or signed | French | Q150 |
| English | Q1860 | ||
| P1559 | name in native language | Willy Rozenbaum | |
| P106 | occupation | physician | Q39631 |
| P1327 | partner in business or sport | Luc Montagnier | Q103598 |
| Françoise Barré-Sinoussi | Q103844 | ||
| Jean-Claude Chermann | Q513246 | ||
| Françoise Brun-Vézinet | Q3086421 | ||
| Christine Rouzioux | Q28595176 | ||
| Marie-Thérèse Nugeyre | Q59592199 | ||
| Françoise Rey | Q86877835 | ||
| Claudine Axler-Blin | Q117278389 | ||
| Sophie Chamaret | Q118557247 | ||
| Jacqueline Gruest | Q118557762 | ||
| Charles Dauguet | Q118558049 | ||
| P21 | sex or gender | male | Q6581097 |
| Q45419512 | Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients |
| Q61457385 | Antiretroviral Therapy Initiation in France |
| Q36152897 | Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. |
| Q43950417 | Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance |
| Q61457422 | BMD Is Reduced in HIV-Infected Men Irrespective of Treatment |
| Q61457534 | Clinical and laboratory findings of disseminated Mycobacterium avium complex infection (DMAC) in a pair matched case-control study |
| Q44973436 | Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. |
| Q54731373 | Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. |
| Q61457467 | Développement d'une génothérapie anti-VIH basée sur les propriétés antivirales de l'interféron bêta |
| Q45664914 | Early impairment of CD8+ T cells immune response against Epstein-Barr virus (EBV) antigens associated with high level of circulating mononuclear EBV DNA load in HIV infection. |
| Q56833989 | Effect of indinavir on HIV-related wasting |
| Q54753583 | Emergence of HIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients. |
| Q45780421 | Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection |
| Q45912283 | HIV experts on the decision to use early ART for prevention in France: are we there yet? |
| Q43850319 | HIV-1 related ischaemic trochlear nerve palsy |
| Q61457543 | Half-dose zidovudine |
| Q40734168 | Human immunodeficiency virus and infected aneurysm of the abdominal aorta: report of three cases. |
| Q33313949 | Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study |
| Q22242256 | Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) |
| Q61457448 | Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients |
| Q44913614 | Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir |
| Q45740040 | Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators |
| Q61457461 | Multiple myeloma in an HIV-positive man presenting with primary cutaneous plasmacytomas and spinal cord compression |
| Q45741363 | Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients |
| Q44753497 | Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure. |
| Q33799563 | Phylogenetic analyses indicate an atypical nurse-to-patient transmission of human immunodeficiency virus type 1 |
| Q61457482 | Rate of detection of human herpesvirus-6 at different stages of HIV infection |
| Q39545667 | Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial |
| Q61457407 | Reduction in Triglyceride Level With N-3 Polyunsaturated Fatty Acids in HIV-Infected Patients Taking Potent Antiretroviral Therapy |
| Q41490072 | Results of culture form colonoscopically obtained specimens for bacteria and fungi in HIV-infected patients with diarrhea. |
| Q33640329 | Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting |
| Q28294098 | Splenic infarction during acute malaria |
| Q50133902 | The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002. |
| Q32054854 | Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection. |
| Q61457477 | Treatment of non-meningeal cryptococcosis in patients with AIDS |
| Q50510849 | Two cases of cytomegalovirus infection revealed by hearing loss in HIV-infected patients. |
| Q28331235 | Vitamin B12 injections in patients treated with zidovudine |
| Q57340363 | What Is a Modest Public Health Impact? |
| Q118558049 | Charles Dauguet |
| Q28595176 | Christine Rouzioux |
| Q117278389 | Claudine Axler-Blin |
| Q103844 | Françoise Barré-Sinoussi |
| Q3086421 | Françoise Brun-Vézinet |
| Q86877835 | Françoise Rey |
| Q118557762 | Jacqueline Gruest |
| Q513246 | Jean-Claude Chermann |
| Q103598 | Luc Montagnier |
| Q59592199 | Marie-Thérèse Nugeyre |
| Q118557247 | Sophie Chamaret |
| Q39055018 | HPA-23 | discoverer or inventor | P61 |